Treatment of Non-Small Cell Lung Cancer with EGFR Mutations
AssigneeJanssen Biotech, Inc.
InventorsRoland Knoblauch, Sheri Moores
Life of this patent
Estimating the term…
Abstract
The present invention relates to treatment of subjects having EGFR exon 20 insertion and other uncommon EGFR mutations.
Claims26
1) A method of treating a subject having cancer that is positive for an EGFR exon 20 mutation, comprising administering a therapeutically effective amount of an isolated bispecific anti-epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody to the subject having cancer that is positive for the EGFR exon 20 mutation.
3) A method of treating a subject having cancer that is positive for an EGFR S768I, L861Q and/or G719X mutation (wherein X is any amino acid other than G), comprising administering a therapeutically effective amount of an isolated bispecific anti-epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody to the subject having cancer.
Dependencies are inferred from the claim text.